Loading...
Loading...
DSGN| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.1M |
| Gross Profit | -0.1M |
| Operating Expense | 22.6M |
| Operating I/L | -22.6M |
| Other Income/Expense | 2.7M |
| Interest Income | 0.0M |
| Pretax | -19.9M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -19.9M |
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company specializing in developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes treatments for Friedreich Ataxia and Myotonic Dystrophy Type-1, both progressive multi-system diseases affecting various organs. Additionally, the company is working on GeneTAC product candidates for other nucleotide repeat expansion-driven monogenic diseases such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy.
